Girolamo Calo, Remo Guerrini, Anna Rizzi, Severo Salvadori, Melissa Burmeister, Daniel R. Kapusta, David G. Lambert, Domenico Regoli
{"title":"UFP-101, a Peptide Antagonist Selective for the Nociceptin/Orphanin FQ Receptor","authors":"Girolamo Calo, Remo Guerrini, Anna Rizzi, Severo Salvadori, Melissa Burmeister, Daniel R. Kapusta, David G. Lambert, Domenico Regoli","doi":"10.1111/j.1527-3458.2005.tb00264.x","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Nociceptin/orphanin FQ modulates various biological functions at central and peripheral levels by selectively activating a G-protein coupled receptor named N/OFQ peptide (NOP) receptor. For extending our knowledge on the biological roles of the N/OFQ - NOP receptor system the identification of selective NOP ligands, especially antagonists, is mandatory. [Nphe<sup>1</sup>, Arg<sup>14</sup>, Lys<sup>15</sup>] N/OFQ-NH<sub>2</sub> (UFP-101) is a novel NOP ligand that was designed by combining, in the same molecule, the [Nphe<sup>1</sup>] chemical modification which eliminates efficacy and the [Arg<sup>14</sup>, Lys<sup>15</sup>] substitution which increases ligand potency and duration of action <i>in vivo.</i> In the present article, we summarize the pharmacological features of UFP-101 as determined in a series of <i>in vitro</i> and <i>in vivo</i> assays. Moreover, some biological actions and possible therapeutic indications of NOP ligands are discussed on the basis of results obtained with UFP-101. Data obtained with this compound were compared with those generated using other NOP antagonists, especially J-113397 and [Nphe<sup>1</sup>]N/OFQ(1-13)-NH<sub>2</sub>, receptor or peptide knockout mice and other pharmacological tools useful for blocking N/OFQ – NOP receptor signaling.</p>\n <p>The analysis of the available data demonstrates that UFP-101 is a useful pharmacological tool for the investigation of the central and peripheral biological functions regulated by the N/OFQ – NOP receptor system and for defining the therapeutic potential of NOP receptor ligands</p>\n </div>","PeriodicalId":94307,"journal":{"name":"CNS drug reviews","volume":"11 2","pages":"97-112"},"PeriodicalIF":0.0000,"publicationDate":"2006-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1527-3458.2005.tb00264.x","citationCount":"99","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS drug reviews","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/j.1527-3458.2005.tb00264.x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 99
Abstract
Nociceptin/orphanin FQ modulates various biological functions at central and peripheral levels by selectively activating a G-protein coupled receptor named N/OFQ peptide (NOP) receptor. For extending our knowledge on the biological roles of the N/OFQ - NOP receptor system the identification of selective NOP ligands, especially antagonists, is mandatory. [Nphe1, Arg14, Lys15] N/OFQ-NH2 (UFP-101) is a novel NOP ligand that was designed by combining, in the same molecule, the [Nphe1] chemical modification which eliminates efficacy and the [Arg14, Lys15] substitution which increases ligand potency and duration of action in vivo. In the present article, we summarize the pharmacological features of UFP-101 as determined in a series of in vitro and in vivo assays. Moreover, some biological actions and possible therapeutic indications of NOP ligands are discussed on the basis of results obtained with UFP-101. Data obtained with this compound were compared with those generated using other NOP antagonists, especially J-113397 and [Nphe1]N/OFQ(1-13)-NH2, receptor or peptide knockout mice and other pharmacological tools useful for blocking N/OFQ – NOP receptor signaling.
The analysis of the available data demonstrates that UFP-101 is a useful pharmacological tool for the investigation of the central and peripheral biological functions regulated by the N/OFQ – NOP receptor system and for defining the therapeutic potential of NOP receptor ligands